Departamento de Oncología, Centro Médico ABC. Mexico City, Mexico.
Unidad Funcional de Oncología Torácica, Instituto Nacional de Cancerología. Mexico City, Mexico.
Salud Publica Mex. 2019 May-Jun;61(3):352-358. doi: 10.21149/10118.
Lung cancer is a major global public health problem, yet the disease is highly stigmatized, which impairs the opportunities to get optimal treatment for these patients. Globally, as well as locally in Mexico, lung cancer is the main cause of cancer-related deaths. Despite this, it is the only one among the five deadliest cancers in Mexico which is not covered by Popular Health Insurance. Lung cancer treatment is a complex algorithm, which requires fully trained personnel to assess each patient in order to determine standard-of-care therapy based on several factors associated with the molecular profile of the tumor, as well as patient characteristics and their financial capabilities. Coupled to this, in the recent decade, several breakthrough therapies have been launched, shifting the outlook for certain patient subgroups. However, none of these novel therapies are currently available to patients who have public-based health insurance. In this paper, we review the inequities present in the Mexican health system and highlight the importance of addressing these opportunities.
肺癌是一个全球性的重大公共卫生问题，但该病受到高度污名化，这影响了为这些患者获得最佳治疗的机会。在全球范围内，以及在墨西哥当地，肺癌是癌症相关死亡的主要原因。尽管如此，它是墨西哥五种最致命癌症中唯一一种未被大众健康保险覆盖的癌症。肺癌的治疗是一个复杂的算法，需要经过全面培训的人员来评估每个患者，以便根据与肿瘤分子特征相关的几个因素以及患者的特征和经济能力来确定标准治疗方案。此外，在过去十年中，已经推出了几种突破性的治疗方法，改变了某些患者亚组的前景。然而，目前拥有公共医疗保险的患者无法获得这些新的治疗方法。在本文中，我们回顾了墨西哥卫生系统中存在的不平等现象，并强调了解决这些问题的重要性。
